KOSDAQBiotech & Pharma006620

DongKoo Bio & Pharma

₩3,245▼ 1.67%2026-11-18 close
Market Cap
₩92.4B
Turnover
₩74,754,910
Volume
20K
Shares out.
28.5M
PER
3.5×
PBR
0.7×
EPS
₩970
Dividend Yield
3.53%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩120 per share · Prices as of the 2026-11-18 close

01

Report overview

Urology Growth Versus a Profit Recovery Still to Prove

DongKoo Bio & Pharma keeps a dermatology prescription leadership and fast urology growth, but operating and net losses since the second quarter of 2026 make profit recovery the central question.

  1. 1

    Pharmaceutical operations generated KRW 116.3 billion in the first half of 2026, or 98.4% of sales, so the business depends heavily on drugs.

  2. 2

    The operating margin fell from 8.7% in 2022 to 3.8% in 2025, and operating profit declined for three straight years from 2023 to 2025.

  3. 3

    After an operating loss of KRW 6.45 billion in the second quarter of 2026, the company posted an operating loss of KRW 2.69 billion in the third quarter, while the net loss attributable to controlling shareholders widened to KRW 8.32 billion.

  4. 4

    Urology prescriptions rose 20.4% in 2025, faster than the market's 14.4%, while investment assets equal about 34% of total assets and add earnings volatility.

  5. 5

    The next checkpoints are the entry of the NCP112 candidate into Phase 2 trials, the outcome of the GMP litigation and the implementation of drug price policy.

02

Business structure

DongKoo Bio & Pharma centers on prescription drugs and quasi-drugs and runs five business units, including new technology business financing, medical services, drug wholesale and consulting, and cosmetics and health functional foods.

Pharmaceutical operations generated KRW 116.3 billion in the first half of 2026, or 98.4% of sales, based on the company's disclosed business-segment data. Urogenital and anal drugs have become the largest product group.

Sales in this group reached KRW 54.1 billion in 2024, up more than 60% from the prior year, and their share of total revenue rose from 13.3% in 2020 to 21.7% in 2024. On a standalone basis in the first half of 2026, the segment recorded KRW 28.3 billion, or 24.3% of sales. Dermatology is moving sideways.

The company kept first place in dermatology prescriptions in 2025 with KRW 31.5 billion, but that was 2.1% lower than the prior year, and skin-applied drugs brought in KRW 9.8 billion on a standalone basis in the first half of 2026.

Reported 2024 sales were KRW 17.8 billion for skin-applied drugs, KRW 21.8 billion for allergy drugs and KRW 19.9 billion for antibiotics.

Urology prescriptions reached KRW 43.5 billion in 2025, up 20.4% from the prior year, outpacing a market growth rate of 14.4%, and the company moved from fifth to fourth place in that market. The runner-up in dermatology prescriptions recorded KRW 20.3 billion, which leaves a wide gap with the leader.

R&D spending was KRW 18.48 billion in 2025, or 8.0% of sales, and KRW 8.77 billion in the first half of 2026, or 7.5% of sales. Investment assets stood at KRW 108.9 billion at the end of June 2026, about 34% of total assets of KRW 318.6 billion.

The company became the largest shareholder of Curient through a joint investment. Shareholding by the largest shareholder and related parties was 37.01% at the end of June 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩62B₩2.2B3.5%
2025Q4₩61.9B₩2.8B4.5%
2026Q1₩58.1B₩1.8B3.1%
2026Q2₩59.5B-₩6.5B−10.9%
2026Q3₩61B-₩2.7B−4.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩195B₩17B₩6.6B8.7%6.5%68.5%
2023₩215.7B₩14.6B₩11.8B6.8%10.7%73.0%
2024₩249.3B₩12.7B₩2B5.1%1.9%131.5%
2025₩242.7B₩9.2B₩50.3B3.8%33.1%121.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On the disclosed annual figures, sales rose from KRW 195 billion in 2022 to KRW 215.7 billion in 2023, up 10.6%, and then to KRW 249.3 billion in 2024, up 15.6%, making 2024 the largest year of 2022 to 2025. Sales were KRW 242.7 billion in 2025, down 2.6% from the prior year.

Operating profit fell from KRW 17 billion in 2022 to KRW 14.6 billion in 2023, down 14.2%, to KRW 12.7 billion in 2024, down 13.2%, and to KRW 9.25 billion in 2025, down 27.1%. Operating profit has decreased for three consecutive years from 2023 to 2025.

The operating margin moved from 8.7% in 2022 to 6.8% in 2023, 5.1% in 2024 and 3.8% in 2025. In its 2024 annual report, the company cited higher headcount, facility investment and R&D as reasons for cost increases that adjusted profitability.

The company attributed the 2024 net income of KRW 1.99 billion partly to one-off items such as valuation losses on investment assets caused by financial market volatility.

Net profit attributable to controlling shareholders was KRW 11.8 billion in 2023, KRW 2.04 billion in 2024, down 82.8%, and KRW 50.3 billion in 2025, up 2,369.7%.

Because 2025 net profit attributable to controlling shareholders was far larger than operating profit, non-operating items such as investment and equity-method results appear to have had a large effect, though the breakdown needs confirmation in the annual report.

Operating cash flow was KRW 16.8 billion in 2022, KRW 3.59 billion in 2023, KRW 17.3 billion in 2024 and minus KRW 4.29 billion in 2025. The debt ratio rose from 73.0% in 2023 to 131.5% in 2024 and was 121.1% in 2025.

Quarterly sales were KRW 62 billion in the third quarter of 2025, KRW 61.9 billion in the fourth quarter, KRW 58.1 billion in the first quarter of 2026, KRW 59.5 billion in the second quarter and KRW 61 billion in the third quarter, so sales have risen for two consecutive quarters since the first quarter of 2026.

Operating profit fell from KRW 2.8 billion in the fourth quarter of 2025 to KRW 1.81 billion in the first quarter of 2026, then turned into an operating loss of KRW 6.45 billion in the second quarter.

The third-quarter operating loss of KRW 2.69 billion was smaller than the second quarter's, but it still represented a swing from profit a year earlier.

Net profit attributable to controlling shareholders was KRW 41.3 billion in the fourth quarter of 2025, which turned positive from a loss, and then recorded losses for three consecutive quarters through the third quarter of 2026, with a net loss of KRW 8.32 billion in the latest quarter.

The sum of the last four quarters' net profit attributable to controlling shareholders was KRW 26.3 billion. Gross margin in the first half of 2026 was 57.9%, below 61.1% a year earlier.

05

Industry analysis

Key industry variables for Korean pharmaceuticals are intensifying competition in generics and changes in the drug pricing system.

The company has said that drug price cuts taking effect from 2026 could shake up both prescription sales and its investment strategy, and its chairman has said mid- to long-term options for smaller drugmakers would need to be reassessed if the policy takes hold.

DongKoo has built a broad investment portfolio, reaching biotech, healthcare and semiconductor or IT companies, on the cash flow from generics and dermatology prescriptions, so pricing policy also bears on its investment capacity.

It has ranked first in dermatology prescriptions since 2013, but prescriptions declined in 2025, and growth in that franchise has slowed. The urology market grew 14.4% in 2025, while the company's urology prescriptions rose 20.4%, lifting its share from 4.3% to 4.5%.

Defending unit prices in urology products is the main challenge in that segment. Compared with peers such as Hanmi Pharm and Yuhan, which build around new drug development and technology exports, DongKoo relies more on prescription sales and improved versions of existing drugs.

Its main pipeline asset is the atopic dermatitis candidate NCP112, which received domestic Phase 2 IND approval after a licensing deal in February 2026. Industry views are that commercialization is still a long way off.

For the sector as a whole, the key test is how smaller drugmakers adjust their growth strategies under the new price regime.

06

Outlook

The company's medium- to long-term plan is to keep its competitiveness in prescription drugs centered on dermatology and urology while growing improved new drugs, biosimilar-type drugs and CDMO services.

Its 2024 annual report named expanding the cosmeceutical line, strengthening CDMO operations and accelerating overseas expansion as priorities. In the pipeline, NCP112 has received domestic Phase 2 IND approval, and the company plans to proceed to Phase 2 trials.

Until the timing and cost of that trial are disclosed, R&D spending is likely to remain at around 7% to 8% of sales. Legal uncertainty also remains.

The regulator revoked the GMP conformity determination for certain solid oral products in 2024, and the company halted manufacturing and sales of the affected items and carried out a recall.

In August 2026 the first-instance court ruled against the company in its suit to overturn the administrative disposition, and the case moved to appeal.

The affected products account for a small share of sales, but the disclosed value of the manufacturing suspension is large, so the outcome of the appeal bears on production operations. In investment assets, changes in the value of the Curient stake remain a variable that can swing quarterly results.

Equity-method investment results turned to a loss of KRW 3.1 billion in the first half of 2026 from a gain of KRW 7.7 billion a year earlier. Press coverage has described the second half of 2026 as the first test separating earnings recovery from legal uncertainty. The next confirmation point is whether the operating margin recovers in the 2026 annual report.

07

Valuation

PER
3.5×
PBR
0.7×
ROE
21.8%
EPS
₩970
BPS
₩4,850
Dividend per share
₩120

The share price currently trades at a low level relative to book net assets, with the price-to-book ratio below 1x. Market capitalization sits below the controlling shareholders' equity of KRW 151.7 billion at the end of 2025.

That means the market is not fully crediting the asset base, and the discount is linked to continuing operating losses, valuation swings in investment assets and legal uncertainty.

The price-to-earnings multiple looks low, but it is calculated on the last four quarters' net profit attributable to controlling shareholders, which totals KRW 26.3 billion and includes non-operating gains and losses.

Because 2025 net profit attributable to controlling shareholders was far above operating profit, the same multiple carries a different meaning on an operating-profit basis. Dividends move with earnings, so past profit swings and the current payout should be read together.

Over several years, the move from a 2024 net loss to a large 2025 profit stands out as a recovery in earnings, but quarterly results have turned loss-making again since 2026.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Dermatology prescription leadership

DongKoo has held the top spot in dermatology prescriptions since 2013, with KRW 31.5 billion in 2025. The prescription base remains a commercial asset even though prescriptions slipped 2.1% last year. The gap with the runner-up remains wide. The network could serve as a distribution channel for future launches.

Faster growth in urology

Urogenital and anal drug sales grew from KRW 18.5 billion in 2020 to KRW 54.1 billion in 2024. Urology prescriptions reached KRW 43.5 billion in 2025, up 20.4%, ahead of a market growth rate of 14.4%. The company's rank rose from fifth to fourth and its share increased from 4.3% to 4.5%. If this continues, the revenue mix could tilt further toward urology.

Sales recovery signs and pipeline

Sales bottomed at KRW 58.1 billion in the first quarter of 2026 and then rose to KRW 59.5 billion and KRW 61 billion, a two-quarter increase. NCP112 has received domestic Phase 2 IND approval, which keeps a new-drug option open. The Curient stake, held alongside the largest-shareholder position, reflects the company's investment strategy.

09

Bear factors

Structural decline in operating profitability

The operating margin fell from 8.7% in 2022 to 3.8% in 2025, less than half its earlier level. An operating loss of KRW 6.45 billion in the second quarter of 2026 was followed by a KRW 2.69 billion loss in the third quarter. In the first half of 2026 gross margin dropped from 61.1% to 57.9%, and selling and administrative costs rose.

Regulatory and legal uncertainty

The regulator revoked the GMP conformity determination for certain solid oral products in 2024, and the company halted sales of the affected items and carried out a recall. The first-instance court ruled against the company in August 2026.

Production and regulatory risk remains until the appeal is decided, and drug price cuts are another variable for prescription sales.

Financial structure and cash flow

Operating cash flow turned to minus KRW 4.29 billion in 2025 from KRW 17.3 billion in 2024. The debt ratio was 131.5% in 2024 and 121.1% in 2025. Investment assets equal about a third of total assets, so equity-method and valuation swings move results.

10

Risk factors

Drug pricing and regulation

If drug price cuts take hold from 2026, unit prices for generics and prescription products could fall. The chairman has said the policy change would force a reassessment of the business structure and mid- to long-term options. The appeal outcome on the GMP disposition could affect production and supply.

Earnings volatility from financial and investment items

Net profit attributable to controlling shareholders reached KRW 50.3 billion in 2025, far above operating profit of KRW 9.25 billion, and quarterly results have since turned to losses. Large swings in non-operating items make quarterly net profit hard to read against operating trends. Valuation changes and equity-method results are largely outside the company's control.

R&D and pipeline

R&D spending was 8.0% of sales in 2025 and 7.5% in the first half of 2026, which is a high share. NCP112 has not yet entered Phase 2, and commercialization would take considerable time. Keeping R&D spending high while operating profit is negative would add to financial pressure.

11

What to watch next

  1. End of March 2027 (statutory filing deadline)

    The 2026 annual report will show the full-year operating margin, operating cash flow, debt ratio and the non-operating makeup of net profit attributable to controlling shareholders. Fourth-quarter 2026 results will first be disclosed there.

  2. May 15, 2027 (statutory deadline)

    The first-quarter 2027 report will show whether the run of operating losses that began in the second quarter of 2026 is reversing. The key test is whether two quarters of sales growth translate into better profit.

  3. Appeal ruling date not yet set

    Watch for the appellate decision in the suit over the GMP conformity revocation and any disclosure on the effect on manufacturing operations.

  4. Phase 2 start date not yet set

    Watch for the announcement of the domestic Phase 2 start for NCP112, along with trial scale and cost plans, and whether R&D stays at a high share of sales.

12

Overall view

DongKoo Bio & Pharma grew sales from 2022 to 2024 on its leadership in dermatology prescriptions and growth in urology. Its operating margin, however, fell from 8.7% in 2022 to 3.8% in 2025, and operating and net losses have continued since the second quarter of 2026.

Sales have risen for two quarters since the first-quarter 2026 low, but a profit recovery has not yet appeared. The large 2025 net profit attributable to controlling shareholders likely reflects heavy non-operating items such as investment and equity-method results, so it should be read apart from operating trends.

On the financial side, the debt ratio is high, operating cash flow turned negative in 2025, and the large investment-asset share adds earnings volatility. On the regulatory side, the appeal in the GMP case and drug price policy are the variables to watch. The 2026 annual report is the next checkpoint for whether the operating margin and cash flow recover.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. jobkorea.co.kr
  3. medipharmhealth.co.kr
  4. jasoseol.com
  5. kpinfo.kr
  6. jobplanet.co.kr
  7. thevc.kr
  8. bebee.com
  9. thebell.co.kr
  10. medipana.com
  11. medipana.com
  12. businesspost.co.kr
  13. butler.works
  14. ibtomato.com
  15. saramin.co.kr
  16. medicopharma.co.kr
  17. pharm.edaily.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis